The use of transgenic mice in pharmacokinetic and pharmacodynamic studies

Journal of Pharmaceutical Sciences

Volumn 90, Issue 4, 2001, Pages 422-435

  Elmquist, William F ^a   Miller, Donald W ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Knockout; Pharmacodynamics; Pharmacokinetics; Transgenic mouse

Indexed keywords

CLINICAL RESEARCH; GENE INSERTION; GENE TECHNOLOGY; GENETIC MANIPULATION; KNOCKOUT MOUSE; NONHUMAN; PHARMACODYNAMICS; SHORT SURVEY; TRANSGENIC MOUSE;

EID: 0035069284     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/1520-6017(200104)90:4<422::AID-JPS1001>3.0.CO;2-Z     Document Type: Short Survey

References (91)

1. Transgenic animals in integrative biology: Approaches and interpretations of outcome
2. Transgenic animals
3. Gene knock-out technology: A methodological overview for the interested novice
4. Inflammatory disease in HLA-B27 transgenic rats
5. Mucosal IL-7-mediated immune responses in chronic colitis-IL-7 transgenic mouse model
6. Transgenic animals with altered high-density lipoprotein composition and functions
7. Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis
8. Transgenic mice overexpressing insulin-like growth factor-II in beta cells develop type 2 diabetes
9. Genetic models for non insulin dependent diabetes mellitus in rodents
10. Transgenic animal models: New avenues in cardiovascular physiology
11. Transgenic animals in biomedical research
12. Genetically engineered mice in drug development
13. Transgenic animals as tools in drug development
14. Transgenic animals in toxicology
15. In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals
16. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
17. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmaco-kinetics of dexamethasone, digoxin, and cyclosporin A
18. Pharmacological insights from P-glycoprotein knock-out mice
19. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
20. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs
21. BBB transport and P-glycoprotein functionality using mdr1a (- / -) and wild type mice. Total brain versus microdialysis concentration profiles of rhodamine-123
22. Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type and mice lacking mdr1a P-glycoprotein
23. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833
24. Physiologically based pharmacokinetics of digoxin in mdr1a knock-out mice
25. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein
26. Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knock-out mice
27. P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier
28. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
29. Role of p-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor
30. Altered disposition and antinociception of [D-Penicillamine2,5] enkephalin in mdr1a-gene-deficient mice
31. Penetration of amitriptyline, but not fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a p-glycoprotein gene disruption
32. Role of p-glycoprotein in drug disposition
33. Effect of the mdr1a p-glycoprotein gene disruption on the tissue distribution of SDZ PSC 833, a multidrug resistance-reversing agent, in mice
34. Disruption of mdr1a p-glycoprotein gene results in dysfunction of the blood-inner ear barrier in mice
35. Spinal cord bioavailability of methlypredinosolone after intravenous and intrathecal administration. The role of p-glycoprotein
36. P-glycoprotein-dependent disposition kinetics of tacrolimus: Studies in mdr1a knock-out mice
37. Altered pharmacokinetics of vinblastine in mdr1a p-glycoprotein deficient mice
38. Contribution of the murine mdr1a p-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with a mdr1a gene disruption
39. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a p-glycoprotein
40. The role of mdr1a p-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice
41. Drug disposition as determined by the interplay between drug-transportering and drug-metabolizing systems
42. P-glycoprotein: A major determinant of rifampicin-inducible expression of cyctochrome P4503A in mice and humans
43. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes
44. Opiate-induced analgesia is increased and prolonged in mice lacking p-glycoprotein
45. Antinoceptive effects of morphine-6-glucouronide in homozygous MDR1a p-glycoprotein knock-out and in wild type mice in the hotplate test
46. Role of blood-brain barrier p-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug
47. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
48. The multidrug resistance protein family
49. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells
50. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2
51. MRP3, an organic anion transporter able to transport anti-cancer drugs
52. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells
53. Characterization of efflux transport of organic anions in a mouse brain capillary endothelial cell line
54. Modulation of multidrug resistance protein expression in porcine brain capillary endothelial cells in vitro
55. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane
56. Secretion of organic anions by hepatocytes: Involvement of homologues of the multidrug resistance protein
57. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells
58. Tissue and cell distribution of the multidrug resistance-associated protein (MRP) in mouse intestine and kidney
59. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines
60. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier
61. Export pumps for anionic conjugates encoded by MRP genes
62. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein
63. Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testiciular tubules against drug-induced damage
64. Mice lacking the multidrug resistance protein 1 are resistant to streptococcus pneumoniae-induced pneumonia
65. Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione
66. The multidrug resistance protein family
67. Multidrug resistance protein 5, a candidate multispecific organic anion transporter
68. Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells
69. New insights into the biology and pharmacology of the multidrug resistance protein (MRP) from gene knock-out models
70. Cytochrome P450-null mice
71. Cypla2(- / -) null mutant mice develop normally but show deficient drug metabolism
72. Neonatal lethality associated with respiratory distress in mice lacking cytochrome P450 1A2
73. Role of CYP1A2 in caffeine pharmacokinetics and metabolism: Studies using mice deficient in CYP1A2
74. Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2
75. Role of CYP2E1 in the hepatotoxicity of acetaminophen
76. Reduction of benzene metabolism and toxicity in mice that lack CYP2E1 expression
77. Humanized xenobiotic response in mice expressing nuclear receptor SXR
78. Pharmacokinetics and antidepressant activity of fluoxetine in transgenic mice with elevated serum alpha-1-acid glycoprotein levels
79. Altered disposition and antidepressant activity of imipramine in transgenic mice with elevated serum alpha-1-acid glycoprotein
80. Steady state kinetics of imipramine in transgenic mice with elevated serum AAG levels
81. Drug binding to human alpha-1-acid glycoprotein in health and disease
82. Intravascular distribution of zidovudine: Role of plasma proteins and whole blood components
83. Development of an in situ mouse brain perfusion model and its application to mdr1a p-glycoprotein-deficient mice
84. Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice
85. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier
86. Conditional Gene Targeting
87. T-cell-specific deletion of a polypeptide N-acetylgalactosaminyl-transferase gene by site-directed recombination
88. Inducible gene targeting in mice
89. Disruption of the c/ebpα Gene in Adult Mouse Liver
90. Targeted DNA recombination in vivo using an adenovirus carrying the cre recombinase gene